Celgene has entered a definitive merger agreement to acquire US-based biopharmaceutical firm Juno Therapeutics for $87 per share, totalling approximately $9bn.

Juno primarily develops chimeric antigen receptor (CAR) T and T-cell receptor (TCR) therapeutics.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The firm’s JCAR017 (lisocabtagene maraleucel; liso-cel) candidate for the treatment of relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL) is expected to bolster Celgene’s lymphoma portfolio.

Anticipated to obtain US regulatory approval next year, JCAR017 is estimated to potentially generate around $3bn in peak sales.

Celgene CEO Mark Alles said: “The acquisition of Juno builds on our shared vision to discover and develop transformative medicines for patients with incurable blood cancers.

“Juno’s advanced cellular immunotherapy portfolio and research capabilities strengthen Celgene’s global leadership in haematology and adds new drivers for growth beyond 2020.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData
“The people at Juno channel their passion for science and patients towards a common goal of finding cures by creating cell therapies that help people live longer, better lives.”

The deal will further add complementary scientific platform and scalable manufacturing capabilities to support Celgene’s position in haematology and oncology segments.

Furthermore, Celgene intends to leverage Juno’s research and development facility in Seattle and the firm’s manufacturing facility in Bothell, Washington for expanding its existing centre of excellence for immuno-oncology translational medicine.

Juno Therapeutics president and CEO Hans Bishop said: “The people at Juno channel their passion for science and patients towards a common goal of finding cures by creating cell therapies that help people live longer, better lives.

“Continuing this work will take scientific prowess, manufacturing excellence and global reach. This union will provide all three.”

Subject to customary closing conditions, the acquisition is expected to be completed in the first quarter of this year.

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now